Arrowhead Pharmaceuticals Inc
ARWR
Company Profile
Business description
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.
Contact
177 E Colorado Boulevard
Suite 700
PasadenaCA91105
USAT: +1 626 304-3400
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 September 2026
Employees
609
Stocks News & Analysis
stocks
Undervalued ASX share with plan to mitigate tariff risk
Shares have dropped 20% in the previous year due to concerns about tariffs.
stocks
Earnings up but shares overvalued for ASX gold miner
Higher gold prices are making a difference to the bottom line but investors overly optimistic.
stocks
Alphabet: Anthropic deal and Gemini momentum stand to deliver; Fair Value up 27%
We see faster cloud growth and improved longer-term profitability for Alphabet.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,295.80 | 26.20 | -0.28% |
| CAC 40 | 8,216.58 | 22.60 | -0.27% |
| DAX 40 | 24,278.63 | 30.15 | -0.12% |
| Dow JONES (US) | 47,706.65 | 162.06 | 0.34% |
| FTSE 100 | 9,696.74 | 42.92 | 0.44% |
| HKSE | 26,346.14 | 87.56 | -0.33% |
| NASDAQ | 23,827.49 | 190.04 | 0.80% |
| Nikkei 225 | 50,219.18 | 293.14 | -0.58% |
| NZX 50 Index | 13,402.66 | 11.07 | 0.08% |
| S&P 500 | 6,890.95 | 15.79 | 0.23% |
| S&P/ASX 200 | 9,012.50 | 16.30 | -0.18% |
| SSE Composite Index | 3,988.22 | 8.72 | -0.22% |